Year-end report 1 May - 30 April 2006/07

Year-end report 1 May - 30 April 2006/07

• Order bookings rose 8 percent to SEK 5,102 M (4,705). Based on unchanged
exchange rates order bookings rose 15 percent. Order backlog amounted to a
record high level of SEK 4,247 M.

• Net sales rose 2 percent to SEK 4,525 M (4,421). Based on unchanged exchange
rates, net sales rose 8 percent.

• Operating profit amounted to SEK 509 M (453) and operating margin was 11
percent (10). Operating profit for the fourth quarter was a record high SEK
263M. 

•Profit after taxes amounted to SEK 346 M (304). Earnings per share after
dilution amounted to SEK 3.70 (3.21).

• Cash flow after investments was a negative SEK 107 M (158). Acquisitions are
included in the amount of SEK -144 M (-195).
•	In accordance with Elekta's distribution policy, a dividend of SEK 1.00 per
share is proposed.
•	For fiscal year 2007/08, Elekta expects a net sales growth of over 10 percent
in local currency and an operating profit growth of over 30 percent.

For the full report, please see enclosed pdf file. 



For further information, please contact: 

Peter Ejemyr, Group VP Corporate Communications 
Tel: +46 733 611 000 (mobile), e-mail: peter.ejemyr@elekta.com 





About Elekta 

Elekta is an international medical-technology Group, providing meaningful
clinical solutions, comprehensive information systems and services for improved
cancer care and management of brain disorders. All of Elekta's solutions employ
non-invasive or minimally invasive techniques and are therefore clinically
effective, gentle on the patient and cost-effective. 

Clinical solutions include among others Leksell Gamma Knife® for non-invasive
treatment of brain disorders and Elekta Synergy® for image guided radiation
therapy (IGRT). Following the acquisition of IMPAC Medical Systems Inc. in April
2005, the Elekta Group is the world's largest supplier of oncology software. 

Elekta's systems and solutions are used at over 4,000 hospitals around the world
to treat cancer and manage clinical operations as well as to diagnose and treat
brain disorders, including tumors, vascular malformations and functional
disorders. 

With approx. 2,000 employees, Elekta's corporate headquarter is located in
Stockholm, Sweden and the company is listed on the Stockholm Stock Exchange
under the ticker EKTAb. For more information about Elekta, please visit
www.elekta.com.